{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:16:04Z","timestamp":1793164564103,"version":"4.5.0"},"reference-count":104,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Inclusion body myositis (IBM) is a progressive muscle disease affecting patients over the age of 40, with distinctive clinical and histopathological features. The typical clinical phenotype is characterized by prominent involvement of deep finger flexors and quadriceps muscles. Less common presentations include isolated dysphagia, asymptomatic hyper-CKemia, and axial or limb weakness beyond the typical pattern. IBM is associated with marked morbidity as majority of patients eventually become wheelchair dependent with limited use of their hands and marked dysphagia. Furthermore, IBM mildly affects longevity with aspiration pneumonia and respiratory complications being the most common cause of death. On muscle biopsy, IBM is characterized by a peculiar combination of endomysial inflammation, rimmed vacuoles, and protein aggregation. These histopathological features are reflective of the complexity of underlying disease mechanisms. No pharmacological treatment is yet available for IBM. Monitoring for swallowing and respiratory complications, exercise, and addressing mobility issues are the mainstay of management. Further research is needed to better understand disease pathogenesis and identify novel therapeutic targets.<\/jats:p>","DOI":"10.3389\/fneur.2022.1020113","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T05:44:52Z","timestamp":1664257492000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":53,"title":["Inclusion body myositis: Update on the diagnostic and therapeutic landscape"],"prefix":"10.3389","volume":"13","author":[{"given":"Elie","family":"Naddaf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.nmd.2013.08.007","article-title":"188th ENMC International Workshop: inclusion body myositis, 2-4 december 2011, naarden, The Netherlands","volume":"23","author":"Rose","year":"2013","journal-title":"Neuromuscul Disord."},{"key":"B2","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1212\/01.wnl.0000277527.69388.fe","article-title":"Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM","volume":"70","author":"Chahin","year":"2008","journal-title":"Neurology."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27716.","article-title":"Atypical presentations of inclusion body myositis: clinical characteristics and long-term outcomes","author":"Alamr","year":"2022","journal-title":"Muscle Nerve"},{"key":"B4","first-page":"34","article-title":"Sporadic-inclusion body myositis (s-IBM) is not so prevalent in Istanbul\/Turkey: a muscle biopsy based survey","volume":"30","author":"Oflazer","year":"2011","journal-title":"Acta Myol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1756-185X.2011.01669.x","article-title":"Incidence and prevalence of idiopathic inflammatory myopathies in South Australia: a 30-year epidemiologic study of histology-proven cases","volume":"16","author":"Tan","year":"2013","journal-title":"Int J Rheum Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3233\/JND-160198","article-title":"A systematic review and meta-analysis of&nbsp;prevalence studies of sporadic inclusion body myositis","volume":"4","author":"Callan","year":"2017","journal-title":"J Neuromuscl Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e2653","DOI":"10.1212\/WNL.0000000000012004","article-title":"Epidemiology and natural history of inclusion body myositis: a 40-year population-based study","volume":"96","author":"Shelly","year":"2021","journal-title":"Neurology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/ana.26412","article-title":"Epidemiology, survival, and clinical characteristics of inclusion body myositis","volume":"92","author":"Lindgren","year":"2022","journal-title":"Ann Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1093\/rheumatology\/keac379","article-title":"Survival and associated comorbidities in inclusion body myositis","volume":"61","author":"Naddaf","year":"2022","journal-title":"Rheumatology (Oxford, England)."},{"key":"B10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.semarthrit.2015.06.005","article-title":"Survival and cancer risk in an unselected and complete Norwegian idiopathic inflammatory myopathy cohort","volume":"45","author":"Dobloug","year":"2015","journal-title":"Semin Arthritis Rheum."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-325141","article-title":"Longitudinal observational study investigating outcome measures for clinical trials in inclusion body myositis","author":"Sangha","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1093\/brain\/awr213","article-title":"Long-term observational study of sporadic inclusion body myositis","volume":"134","author":"Benveniste","year":"2011","journal-title":"Brain"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1093\/brain\/awr217","article-title":"A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities","volume":"134","author":"Cox","year":"2011","journal-title":"Brain"},{"key":"B14","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1212\/WNL.55.2.296","article-title":"Disease progression in sporadic inclusion body myositis: observations in 78 patients","volume":"55","author":"Peng","year":"2000","journal-title":"Neurology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1097\/PHM.0b013e31818a50e2","article-title":"Dysphagia in inclusion body myositis: clinical features, management, and clinical outcome","volume":"87","author":"Oh","year":"2008","journal-title":"Am J Phys Med Rehabil."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1212\/01.WNL.0000145834.17020.86","article-title":"ter Laak HJ, Zimmerman C, Schelhaas HJ, et al. Primary respiratory failure in inclusion body myositis","volume":"63","author":"Voermans","year":"2004","journal-title":"Neurology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.nmd.2012.05.004","article-title":"Quadriceps strength is a sensitive marker of disease progression in sporadic inclusion body myositis","volume":"22","author":"Allenbach","year":"2012","journal-title":"Neuromuscul Disord."},{"key":"B18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4081\/ni.2013.e11","article-title":"Asymptomatic hyper-creatine-kinase-emia as sole manifestation of inclusion body myositis","volume":"5","author":"Finsterer","year":"2013","journal-title":"Neurol Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1007\/s00415-009-5229-9","article-title":"Detecting dysphagia in inclusion body myositis","volume":"256","author":"Cox","year":"2009","journal-title":"J Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/mus.24060","article-title":"Inclusion-body myositis presenting with facial diplegia","volume":"49","author":"Ghosh","year":"2014","journal-title":"Muscle Nerve."},{"key":"B21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.nmd.2019.12.001","article-title":"Myopathies presenting with head drop: Clinical spectrum and treatment outcomes","volume":"30","author":"Alhammad","year":"2020","journal-title":"Neuromuscul Disord."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1007\/s00415-005-0884-y","article-title":"Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients","volume":"252","author":"Badrising","year":"2005","journal-title":"J Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/mus.26914","article-title":"Myopathies with finger flexor weakness: not only inclusion-body myositis","volume":"62","author":"Nicolau","year":"2020","journal-title":"Muscle Nerve."},{"key":"B24","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/ana.410380504","article-title":"Inclusion body myositis and myopathies","volume":"38","author":"Griggs","year":"1995","journal-title":"Ann Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/brain\/112.3.727","article-title":"Inclusion body myositis. observations in 40 patients","volume":"112","author":"Lotz","year":"1989","journal-title":"Brain"},{"key":"B26","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/CND.0000000000000113","article-title":"Clinical and electrophysiological findings in hereditary inclusion body myopathy compared with sporadic inclusion body myositis","volume":"17","author":"Kazamel","year":"2016","journal-title":"J Clin Neuromuscul Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1093\/rheumatology\/keab754","article-title":"Inclusion body myositis: correlation of clinical outcomes with histopathology, electromyography and laboratory findings","volume":"61","author":"Pinto","year":"2022","journal-title":"Rheumatology (Oxford, England)."},{"key":"B28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/ana.410160207","article-title":"Monoclonal antibody analysis of mononuclear cells in myopathies. II: phenotypes of autoinvasive cells in polymyositis and inclusion body myositis","volume":"16","author":"Engel","year":"1984","journal-title":"Ann Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1001\/archneur.1991.00530240033013","article-title":"Amyloid filaments in inclusion body myositis. novel findings provide insight into nature of filaments","volume":"48","author":"Mendell","year":"1991","journal-title":"Archives Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S0960-8966(02)00098-6","article-title":"Inclusion body myositis: morphological clues to correct diagnosis","volume":"12","author":"Dahlbom","year":"2002","journal-title":"Neuromuscul Disord."},{"key":"B31","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1212\/WNL.0000000000000642","article-title":"Evaluation and construction of diagnostic criteria for inclusion body myositis","volume":"83","author":"Lloyd","year":"2014","journal-title":"Neurology."},{"key":"B32","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/ana.410430606","article-title":"Amyloid myopathy: an underdiagnosed entity","volume":"43","author":"Spuler","year":"1998","journal-title":"Ann Neurol."},{"key":"B33","first-page":"103","article-title":"Diagnostic value of markers of muscle degeneration in sporadic inclusion body myositis","volume":"30","author":"Dubourg","year":"2011","journal-title":"Acta Myol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/2051-5960-1-29","article-title":"Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies","volume":"1","author":"Hiniker","year":"2013","journal-title":"Acta Neuropathol Communications."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e004552","DOI":"10.1136\/bmjopen-2013-004552","article-title":"retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis","volume":"4","author":"Brady","year":"2014","journal-title":"BMJ Open."},{"key":"B36","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/nan.12149","article-title":"Mitochondrial and inflammatory changes in sporadic inclusion body myositis","volume":"41","author":"Rygiel","year":"2015","journal-title":"Neuropathol Appl Neurobiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.nmd.2014.06.436","article-title":"An analysis of the sensitivity and specificity of MHC-I and MHC-II immunohistochemical staining in muscle biopsies for the diagnosis of inflammatory myopathies","volume":"24","author":"Rodr\u00edguez Cruz","year":"2014","journal-title":"Neuromuscul Disord."},{"key":"B38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/brain\/120.1.39","article-title":"Polymyositis with cytochrome oxidase negative muscle fibres. Early quadriceps weakness and poor response to immunosuppressive therapy","volume":"120","author":"Blume","year":"1997","journal-title":"Brain"},{"key":"B39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jns.2008.11.010","article-title":"Inflammatory myopathies with mitochondrial pathology and protein aggregates","volume":"278","author":"Temiz","year":"2009","journal-title":"J Neurol Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00296-019-04314-8","article-title":"Polymyositis with mitochondrial pathology or atypical form of sporadic inclusion body myositis: case series and review of the literature","volume":"39","author":"Papadimas","year":"2019","journal-title":"Rheumatol Int."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1093\/jnen\/nlab101","article-title":"Diagnosis and clinical development of sporadic inclusion body myositis and polymyositis with mitochondrial pathology: a single-center retrospective analysis","volume":"80","author":"Winkler","year":"2021","journal-title":"J Neuropathol Exp Neurol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e910","DOI":"10.1212\/WNL.0000000000008863","article-title":"Granulomatosis-associated myositis: high prevalence of sporadic inclusion body myositis","volume":"94","author":"Dieudonn\u00e9","year":"2020","journal-title":"Neurology."},{"key":"B43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.nmd.2018.10.007","article-title":"Myopathies featuring non-caseating granulomas: Sarcoidosis, inclusion body myositis and an unfolding overlap","volume":"29","author":"Alhammad","year":"2019","journal-title":"Neuromuscul Disord."},{"key":"B44","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ana.23822","article-title":"Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis","volume":"73","author":"Pluk","year":"2013","journal-title":"Ann Neurol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/ana.23840","article-title":"Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis","volume":"73","author":"Larman","year":"2013","journal-title":"Ann Neurol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"384","DOI":"10.55563\/clinexprheumatol\/r625rm","article-title":"Diagnostic and prognostic value of anti-cN1A antibodies in inclusion body myositis","volume":"40","author":"Salam","year":"2022","journal-title":"Clin Exp Rheumatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/acr.22600","article-title":"Cytosolic 5'-nucleotidase 1A as a target of circulating autoantibodies in autoimmune diseases","volume":"68","author":"Lloyd","year":"2016","journal-title":"Arthritis Care Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1136\/annrheumdis-2014-206691","article-title":"Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases","volume":"75","author":"Herbert","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1002\/mus.24661","article-title":"Magnetic resonance imaging pattern recognition in sporadic inclusion-body myositis","volume":"52","author":"Tasca","year":"2015","journal-title":"Muscle Nerve."},{"key":"B50","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/mus.26813","article-title":"Quantitative muscle MRI study of patients with sporadic inclusion body myositis","volume":"61","author":"Ansari","year":"2020","journal-title":"Muscle Nerve."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/rheumatology\/ker001","article-title":"Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis","volume":"50","author":"Cox","year":"2011","journal-title":"Rheumatology (Oxford, England)."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/mus.1178","article-title":"Patterns of muscle involvement in inclusion body myositis: clinical and magnetic resonance imaging study","volume":"24","author":"Phillips","year":"2001","journal-title":"Muscle Nerve."},{"key":"B53","first-page":"27","article-title":"Muscle MRI for Neuromuscular Disorders","author":"Nicolau","year":"2020","journal-title":"Pract Neurol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1093\/brain\/aww024","article-title":"Association of inclusion body myositis with T cell large granular lymphocytic leukaemia","volume":"139","author":"Greenberg","year":"2016","journal-title":"Brain"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/leu.2011.107","article-title":"Refining the diagnosis of T-cell large granular lymphocytic leukemia by combining distinct patterns of antigen expression with T-cell clonality studies","volume":"25","author":"Ohgami","year":"2011","journal-title":"Leukemia."},{"key":"B56","doi-asserted-by":"publisher","first-page":"787","DOI":"10.2217\/fon.12.75","article-title":"Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets","volume":"8","author":"Leblanc","year":"2012","journal-title":"Future Oncology (London, England)."},{"key":"B57","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology."},{"key":"B58","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1212\/WNL.58.2.326","article-title":"Intravenous immunoglobulin for dysphagia of inclusion body myositis","volume":"58","author":"Cherin","year":"2002","journal-title":"Neurology."},{"key":"B59","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1136\/jnnp-2014-310008","article-title":"Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement","volume":"87","author":"Goyal","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3390\/cells10051146","article-title":"Anti-cN1A antibodies are associated with more severe dysphagia in sporadic inclusion body Myositis","volume":"10","author":"Lucchini","year":"2021","journal-title":"Cells"},{"key":"B61","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.nmd.2018.06.005","article-title":"Sensitivity and clinical utility of the anti-cytosolic 5'-nucleotidase 1A (cN1A) antibody test in sporadic inclusion body myositis: report of 40 patients from a single neuromuscular center","volume":"28","author":"Felice","year":"2018","journal-title":"Neuromuscul Disord."},{"key":"B62","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1136\/annrheumdis-2016-210282","article-title":"Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis","volume":"76","author":"Lilleker","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B63","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3389\/fimmu.2019.00745","article-title":"Anti-NT5c1A autoantibodies as biomarkers in inclusion body myositis","volume":"10","author":"Amlani","year":"2019","journal-title":"Front Immunol."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27157","article-title":"Anti-cN1A antibodies do not correlate with specific clinical, electromyographic, or pathological findings in sporadic inclusion body myositis","author":"Paul","year":"2020","journal-title":"Muscle Nerve."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1093\/brain\/123.10.2030","article-title":"Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies","volume":"123","author":"Amemiya","year":"2000","journal-title":"Brain"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1212\/01.wnl.0000265398.77681.09","article-title":"cell receptor profiling in muscle and blood lymphocytes in sporadic inclusion body myositis","volume":"69","author":"Salajegheh","year":"2007","journal-title":"Neurology."},{"key":"B67","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jns.2008.12.024","article-title":"CCR7+ myeloid dendritic cells together with CCR7+ T cells and CCR7+ macrophages invade CCL19+ nonnecrotic muscle fibers in inclusion body myositis","volume":"279","author":"Tateyama","year":"2009","journal-title":"J Neurol Sci."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1093\/brain\/awz207","article-title":"Highly differentiated cytotoxic T cells in inclusion body myositis","volume":"142","author":"Greenberg","year":"2019","journal-title":"Brain."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200013","article-title":"Immunophenotyping of inclusion body myositis blood T and NK cells","author":"Goyal","year":"2022","journal-title":"Neurology."},{"key":"B70","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1002\/art.27665","article-title":"Expanded T cell receptor V\u03b2-restricted T cells from patients with sporadic inclusion body myositis are proinflammatory and cytotoxic CD28null T cells","volume":"62","author":"Pandya","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B71","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jneuroim.2012.04.007","article-title":"Frequency of autoantibodies and correlation with HLA-DRB1 genotype in sporadic inclusion body myositis (s-IBM): a population control study","volume":"249","author":"Rojana-Udomsart","year":"2012","journal-title":"J Neuroimmunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/art.40045","article-title":"Immune-Array analysis in sporadic inclusion body myositis reveals hla-drb1 amino acid heterogeneity across the myositis spectrum","volume":"69","author":"Rothwell","year":"2017","journal-title":"Arthritis Rheumatol (Hoboken, NJ)."},{"key":"B73","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.nmd.2009.07.015","article-title":"Sporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotype","volume":"19","author":"Mastaglia","year":"2009","journal-title":"Neuromuscul Disord."},{"key":"B74","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/mus.21386","article-title":"Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis","volume":"40","author":"Salajegheh","year":"2009","journal-title":"Muscle Nerve."},{"key":"B75","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/j.1750-3639.2001.tb00390.x","article-title":"Increased expression of the normal cellular isoform of prion protein in inclusion-body myositis, inflammatory myopathies and denervation atrophy","volume":"11","author":"Zanusso","year":"2001","journal-title":"Brain pathology (Zurich, Switzerland)."},{"key":"B76","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/0140-6736(92)90388-J","article-title":"beta-Amyloid protein immunoreactivity in muscle of patients with inclusion-body myositis","volume":"339","author":"Askanas","year":"1992","journal-title":"Lancet."},{"key":"B77","doi-asserted-by":"publisher","first-page":"eabi9196","DOI":"10.1126\/scitranslmed.abi9196","article-title":"Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis","volume":"14","author":"Britson","year":"2022","journal-title":"Sci Transl Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1042\/CS20160080","article-title":"Mitochondrial DNA disturbances and deregulated expression of oxidative phosphorylation and mitochondrial fusion proteins in sporadic inclusion body myositis","volume":"130","author":"Catal\u00e1n-Garc\u00eda","year":"2016","journal-title":"Clin Sci."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1101\/2021.06.30.450477","article-title":"Comprehensive transcriptomic analysis shows disturbed calcium homeostasis and deregulation of T lymphocyte apoptosis in inclusion body myositis","author":"Johari","year":"2022","journal-title":"J Neurol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.expneurol.2006.12.014","article-title":"Endoplasmic reticulum stress induces myostatin precursor protein and NF-kappaB in cultured human muscle fibers: relevance to inclusion body myositis","volume":"204","author":"Nogalska","year":"2007","journal-title":"Exp Neurol."},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26304","article-title":"Muscle transcriptomics shows overexpression of cadherin 1 in inclusion body myositis","author":"Ikenaga","year":"2022","journal-title":"Ann Neurol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/BOR.0b013e3282efdc7c","article-title":"Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis","volume":"19","author":"Askanas","year":"2007","journal-title":"Curr Opin Rheumatol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"414","DOI":"10.55563\/clinexprheumatol\/pp0oso","article-title":"The role of protein aggregation in the pathogenesis of inclusion body myositis","volume":"40","author":"Snedden","year":"2022","journal-title":"Clin Exp Rheumatol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1177\/000348940811701210","article-title":"Validity and reliability of the Eating Assessment Tool (EAT-10)","volume":"117","author":"Belafsky","year":"2008","journal-title":"Ann Otol Rhinol Laryngol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"116764","DOI":"10.1016\/j.jns.2020.116764","article-title":"Obstruction-related dysphagia in inclusion body myositis: cricopharyngeal bar on videofluoroscopy indicates risk of aspiration","volume":"413","author":"Taira","year":"2020","journal-title":"J Neurol Sci."},{"key":"B86","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s004150050005","article-title":"High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study","volume":"247","author":"Walter","year":"2000","journal-title":"J Neurol."},{"key":"B87","first-page":"838","article-title":"Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients","volume":"30","author":"Dobloug","year":"2012","journal-title":"Clin Exp Rheumatol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/sms.14079","article-title":"Effects of blood-flow restricted resistance training on mechanical muscle function and thigh lean mass in sIBM patients","volume":"32","author":"J\u00f8rgensen","year":"2022","journal-title":"Scand J Med Sci Sports."},{"key":"B89","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1080\/03009742.2017.1423109","article-title":"Blood-flow restricted resistance training in patients with sporadic inclusion body myositis: a randomized controlled trial","volume":"47","author":"J\u00f8rgensen","year":"2018","journal-title":"Scand J Rheumatol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41584-019-0186-x","article-title":"Inclusion body myositis: clinical features and pathogenesis","volume":"15","author":"Greenberg","year":"2019","journal-title":"Nature reviews Rheumatology."},{"key":"B91","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3390\/cells10020255","article-title":"Lithium and therapeutic targeting of GSK-3","volume":"10","author":"Snitow","year":"2021","journal-title":"Cells."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1212\/WNL.58.7.1081","article-title":"pilot randomized trial of oxandrolone in inclusion body myositis","volume":"58","author":"Rutkove","year":"2002","journal-title":"Neurology."},{"key":"B93","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.ymthe.2017.02.015","article-title":"Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes","volume":"25","author":"Mendell","year":"2017","journal-title":"Mol Ther."},{"key":"B94","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S1474-4422(19)30200-5","article-title":"Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Hanna","year":"2019","journal-title":"Lancet Neurol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0006-291X(03)01254-3","article-title":"Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1","volume":"307","author":"Hargitai","year":"2003","journal-title":"Biochem Biophys Res Commun."},{"key":"B96","doi-asserted-by":"publisher","first-page":"331ra41","DOI":"10.1126\/scitranslmed.aad4583","article-title":"Targeting protein homeostasis in sporadic inclusion body myositis","volume":"8","author":"Ahmed","year":"2016","journal-title":"Sci Transl Med"},{"key":"B97","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/ncb2152","article-title":"and mTOR regulate autophagy through direct phosphorylation of Ulk1","volume":"13","author":"Kim","year":"2011","journal-title":"Nat Cell Biol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1212\/WNL.0000000000200188","article-title":"Inclusion body myositis: autoimmune or myodegenerative disease?","volume":"98","author":"Mammen","year":"2022","journal-title":"Neurology."},{"key":"B99","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1146\/annurev-med-050715-104343","article-title":"Innate immunity and neurodegeneration","volume":"69","author":"Labzin","year":"2018","journal-title":"Annu Rev Med."},{"key":"B100","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2217\/pme.11.7","article-title":"The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?","volume":"8","author":"Lillie","year":"2011","journal-title":"Per Med."},{"key":"B101","doi-asserted-by":"publisher","first-page":"e174","DOI":"10.1212\/WNL.0000000000012998","article-title":"N-of-1 trials in neurology: a systematic review","volume":"98","author":"Stunnenberg","year":"2022","journal-title":"Neurology."},{"key":"B102","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/hmg\/ddm037","article-title":"Transgenic expression of inclusion body myopathy associated mutant p97\/VCP causes weakness and ubiquitinated protein inclusions in mice","volume":"16","author":"Weihl","year":"2007","journal-title":"Hum Mol Genet."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1093\/hmg\/ddq050","article-title":"Transgenic mice expressing mutant forms VCP\/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone","volume":"19","author":"Custer","year":"2010","journal-title":"Hum Mol Genet."},{"key":"B104","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/mus.23522","article-title":"A progressive translational mouse model of human valosin-containing protein disease: the VCP(R155H\/+) mouse","volume":"47","author":"Nalbandian","year":"2013","journal-title":"Muscle Nerve."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1020113\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T05:45:02Z","timestamp":1664257502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1020113\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":104,"alternative-id":["10.3389\/fneur.2022.1020113"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.1020113","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]},"article-number":"1020113"}}